Therapy Areas
All Sessions
Resectable NSCLC
Advanced NSCLC
SCLC
Biomarkers
Drug Classes
Targeted Therapies
Immunotherapies
ADCs
Industry Sponsored
Featured Sessions
First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
Latest Advances in Frontline EGFR+ NSCLC
} 14 min
Unlocking New Potentials in EGFR-Mutant NSCLC
} 30 min
Best Practices in Managing Adverse Events with ADCs in NSCLC
} 18 min
From Our Annual Summit
ILCS Sessions
New standards in EGFR- and ALK-positive NSCLC
Other actionable genomic alterations, incl. HER2 and ROS1
Targeting (K)RAS with new compounds
The ADC wave: integrating new agents in NSCLC
New compounds and combinations for non-oncogene-addicted advanced NSCLC
Panel: open questions & patient cases
Open Discussion on Patient Cases
} 22 min
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
} 32 min
Expert Insights
Webinars
2026 Year in Review
Learn more about the event →
2025 Approvals & Highlights
} 1 h 49 min
Targeted Therapies in NSCLC
} 1h 30 min
Immunotherapies in NSCLC
} 1h 47 min
The Reading Room
Articles & Research
South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in
A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival
SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide
Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC
Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC
Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling
VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update
First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg
Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months
Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study
Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue
Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung
Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey
Industry Sponsored
Featured Sessions
One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey
First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
Latest Advances in Frontline EGFR+ NSCLC
} 14 min
Unlocking New Potentials in EGFR-Mutant NSCLC
} 30 min
Best Practices in Managing Adverse Events with ADCs in NSCLC
} 18 min
From Our Annual Summit
ILCS Sessions
New standards in EGFR- and ALK-positive NSCLC
Other actionable genomic alterations, incl. HER2 and ROS1
Targeting (K)RAS with new compounds
The ADC wave: integrating new agents in NSCLC
New compounds and combinations for non-oncogene-addicted advanced NSCLC
Panel: open questions & patient cases
Open Discussion on Patient Cases
} 22 min
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
} 32 min
Expert Insights
Webinars
2026 Year in Review
Learn more about the event →
2025 Approvals & Highlights
} 1 h 49 min
Targeted Therapies in NSCLC
} 1h 30 min
Immunotherapies in NSCLC
} 1h 47 min
The Reading Room
Articles & Research
South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in
A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival
SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide
Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC
Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC
Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling
VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries
Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial
Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE
Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC
TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC
ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational
Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update
First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg
Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months
Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study
Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue
Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung
Two-thirds of patients with PD-L1-high NSCLC received first-line immunotherapy alone in a real-world survey
A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC
Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation
AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy
KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials
Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial
High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC
Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study
Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis
Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC
Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1
Sevabertinib approved in the US for untreated HER2-mutant NSCLC
Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone
First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC
HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China
WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening
ARROS-1: first-line zidesamtinib responds in over 90% of ROS1-positive NSCLC
WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery
DESTINY-Lung04: first-line T-DXd adds six months of PFS, no interim survival gain
PAPILLON final OS: 34.3 vs 27.9 months, HR 0.87 not significant after 76% crossover